On November 18, 2021 Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing transformative treatments based on breakthrough discoveries, reported the appointment of Dr. Sanjay Aggarwal as the company’s chief medical officer (Press release, Apollo Therapeutics, NOV 18, 2021, View Source [SID1234595804]). Dr. Aggarwal will be based in the company’s U.S. facility located at the Cambridge Innovation Center in Cambridge, Mass.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Sanjay is a highly accomplished clinical leader whose experience developing promising therapeutics through to regulatory approval will be incredibly valuable to Apollo as we move our lead programs forward," said Dr. Richard Mason, CEO of Apollo. "We are proud to have him as a leader of our newly opened Boston facility where we look forward to growing our presence in the United States."

Dr. Aggarwal joins Apollo with more than 20 years in the biopharmaceutical industry, including extensive experience in building and leading clinical development teams, as well as a track record of taking drugs through development to successful regulatory approvals. Dr. Aggarwal was most recently chief medical officer at Angiocrine Bioscience, a clinical-stage cell and gene therapy company. Before this, he was the architect of the Rezurock (belumosudil) Phase 2 and 3 development programs at Kadmon, leading to its FDA approval for chronic graft versus host disease. Prior to joining Kadmon, Dr. Aggarwal was the global development lead for Kyprolis (carfilzomib) at Amgen, leading to its approval in multiple myeloma in the U.S., E.U. and numerous additional countries.

Earlier in his career, Dr. Aggarwal held positions of increasing responsibility in both biotech (Exelixis, Onyx Pharmaceuticals) and pharma (GSK, Novartis and Sanofi), overseeing development of early- and late-stage assets across several therapeutic areas with roles in the U.S., Europe and Asia-Pacific. He studied mathematics and medicine to earn his medical degree from The University of Cambridge. He has an MBA from The University of Chicago Booth School of Business. Clinically, he trained in internal medicine and public health and is a member of the Royal College of Physicians.

"Apollo has built an impressive pipeline of therapeutic programs based on breakthrough discoveries that hold tremendous promise across multiple disease areas," said Dr. Aggarwal. "I look forward to advancing the lead programs into clinical investigation and working with the team to further build the company by acquiring clinical-stage assets."

On November 18, 2021 Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, reported that data on BTM-3566, in development for the treatment of hematological malignancies including Diffuse Large B-cell Lymphoma, was selected for an oral presentation at the 63rd Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), being held from December 11- 14, 2021, virtually and in-person in Atlanta (Press release, Bantam Pharmaceutical, NOV 18, 2021, View Source [SID1234595823]). Dr. Adrian Schwarzer, MD, PhD, Hannover Medical School, will present non-clinical research on the activity and mechanism of BTM-3566 a novel, oral compound that targets mitochondrial dynamics leading to cellular stress and tumor cell apoptosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the abstract and oral presentation session are as follows:

Title

BTM-3566, a Novel Activator of the Mitochondrial Stress Response Promotes Robust Therapeutic Responses in Vitro and In Vivo in Diffuse Large B-Cell Lymphoma

Date

Monday, December 13, 2021, 4:00 P.M. ET

Location

Georgia World Congress Center, Room B213-B214, Level 2

Presenter

Adrian Schwarzer, MD, PhD, Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Abstract

Available online at: View Source

Accepted abstracts are currently available in a special online-only issue of Blood, ASH (Free ASH Whitepaper)’s official journal, at View Source

About BTM-3566

BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique and differentiated from other therapeutics, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is being completed for submission in Q1 2022.

On November 18, 2021 Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, reported that Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development will present at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 3:55 pm ET (Press release, Athenex, NOV 18, 2021, https://ir.athenex.com/news-releases/news-release-details/athenex-present-evercore-isi-4th-annual-healthconx-conference [SID1234595772]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation and replay will be available in the "Events & Presentations" section of the Athenex website at View Source An audio archive of the webcast will also be available on Athenex’s website for the following 90 days.

On November 18, 2021 RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, reported an underwritten public offering of American Depositary Shares ("ADSs") (Press release, RedHill Biopharma, NOV 18, 2021, View Source [SID1234595788]). Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. All of the ADSs to be sold in the offering will be offered by RedHill. RedHill has granted the underwriter a 30-day option to purchase up to an additional 15 percent of the number of ADSs offered in the public offering.

Cantor Fitzgerald & Co. is acting as sole bookrunner for the proposed offering.

RedHill intends to use the net proceeds of the offering to fund its commercialization activities, clinical development programs and for acquisitions and general corporate purposes.

The securities described above will be offered by RedHill pursuant to a shelf registration statement on Form S-3 (No. 333-232777) declared effective by the Securities and Exchange Commission (the "SEC") on August 8, 2019.

The securities will be offered only by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at View Source Copies of the preliminary prospectus supplement, when available, and the accompanying prospectus relating to the offering may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, New York 10022, Attn: Capital Markets Department, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 18, 2021 BAKX Therapeutics reported it closed $25 million in a Series A fundraising led by AB Magnitude Ventures Group with Ipsen Pharma SA and Sherpa Healthcare Partners (Press release, Bakx Therapeutics, NOV 18, 2021, View Source [SID1234595805]). The new funding will enable the company to drive its BAKX Activator Program into the clinic in hematologic malignancies and solid tumors and to advance additional targets for solid tumors and prevention of resistance. The financing comes on the heels of the company’s recent announcement of a partnership comprising up to $852 million in upfront and potential milestone payments with Ipsen, a global biopharmaceutical company, to research, develop, manufacture and commercialize the company’s lead candidate, BKX-001, as a potential treatment for leukemia, lymphoma and solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sree Kant, founder and CEO of BAKX Therapeutics, said, "BAKX brings together the world’s most comprehensive knowledge of the mitochondrial apoptosis pathway with industry leading structure-based drug design and computational drug discovery techniques. Our pro-apoptotic programs were developed on the innovative work of our scientific co-founders, Loren D. Walensky of Dana-Farber Cancer Institute and Evripidis Gavathiotis of Albert Einstein College of Medicine, who are the world’s leading experts in pro-apoptotic BAX/BAK activation pathway. Together they uncovered novel methods for solving the unique challenges of exploiting conformationally dynamic proteins to induce cancer cell death while sparing healthy cells."

Kant added, "Following on our collaboration with Ipsen announced in July, the new capital will support more rapid advancement into the clinic of our pipeline of novel therapeutic candidates for solid tumors and turbocharge the deployment of our computational platform to drug conformationally dynamic proteins in the mitochondrial apoptosis pathway. We are grateful to our investors who share our vision and are singularly focused on our aim to develop new therapeutics that successfully address for the first time high-value, well validated, apoptosis targets."

"Many companies have focused on targeting the pro-survival proteins, Bcl-2, Bcl-xl and Mcl-1, which have been effective for treatment of certain leukemias. Unfortunately, they have limitations like resistance in hematological malignancies and inability to achieve dosing efficacy in solid tumors," said Yibing Shan, Ph.D., founding managing director of AB Magnitude Ventures Group, who has also joined BAKX in the role of chief computational scientist. "BAKX instead is successfully activating pro-apoptotic proteins such as BAX and BAK using a combination of unsurpassed target and pathway knowledge, deep expertise in conformationally dynamic protein interactions, and new, highly innovative computational methodologies for identifying cryptic sites and simulating protein interactions in the membrane. I am excited to support the company in this round as well as drive the deployment of the BAKX computational drug discovery platform in the field of apoptosis."

Philippe Lopes-Fernandes, executive vice president and chief business officer at Ipsen, said, "At Ipsen we believe great partnerships create great possibilities and our collaboration with BAKX is an example of this with our investment in the future of BAKX, alongside our collaboration on the BKX-001 program. We support and congratulate BAKX on raising additional capital as we work together to advance BKX-001 in what is a groundbreaking approach to inducing cancer cell death. We share BAKX’s ambition to bring this innovation to people living with cancer around the world."